LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Listă Acțiuni・Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc

Închisă

1.62 -8.47

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.6099999999999999

Maxim

1.6400000000000001

Indicatori cheie
By Trading Economics
Venit	-23T -3.5M
EPS	-0.06
Angajați	7
EBITDA	2.4M -3.5M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+237.42% upside

Dividende
By Dow Jones
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	2.4M 100M
Deschiderea anterioară	10.09
Închiderea anterioară	1.62

Aldeyra Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 mar. 2026, 13:34 UTC

Principalele dinamici ale pieței

Aldeyra Therapeutics Shares Fall as Drug Rejected by Regulator on Efficacy Concerns

16 dec. 2025, 11:43 UTC

Principalele dinamici ale pieței

Aldeyra Shares Fall Premarket After FDA Extends Reproxalap Review

Comparație

Modificare preț

Aldeyra Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

237.42% sus

Prognoză pe 12 luni

Medie 5.5 USD 237.42%

Maxim 9 USD

Minim 2 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAldeyra Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 2 analiști care au acordat evaluări ale acțiunilor Aldeyra Therapeutics Inc - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.